MSI Methylation Sciences raises $19M for depression drug work

Canada's MSI Methylation Sciences has rounded up $19 million in venture cash to back its work on new drugs based on compounds which have already achieved proof-of-concept data. Inventages led the round for the developer, which is focused on depression. "We look forward to working with the Inventages team to progress our lead through clinical trials, said CEO Barry Guld. "We were pleased to have the full support of our current investor group including the Working Opportunity Fund, BC Advantage Funds and several local angel investors." Release

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.